Dalteparin
- Generic Name
- Dalteparin
- Brand Names
- Fragmin
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- S79O08V79F
- Background
Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000. LMWHs have a more pre...
- Indication
Dalteparin is used as a prophylaxis for deep-vein thrombosis and pulmonary embolisms in patients undergoing general surgery (e.g., abdominal, gynecologic, urologic), and in patients with acute medical conditions (e.g. cancer, bed rest, heart failure, severe lung disease). It is also used in patients who have severely restricted mobility, which poses a risk f...
- Associated Conditions
- Cardiovascular Events, Clotting, Deep Vein Thrombosis, Symptomatic Venous Thromboembolism, Venous Thromboembolism
- Associated Therapies
- -
Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery
- First Posted Date
- 2010-02-03
- Last Posted Date
- 2022-08-05
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 16
- Registration Number
- NCT01061411
- Locations
- 🇳🇱
Academ Zienkenhuis Bij De University, Amsterdam, Netherlands
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
The Clinical Utility of Thrombelastography in Guiding Prophylaxis of Venous Thromboembolism Following Trauma
- Conditions
- Interventions
- First Posted Date
- 2010-01-15
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Denver Health and Hospital Authority
- Target Recruit Count
- 50
- Registration Number
- NCT01050153
- Locations
- 🇺🇸
Denver Health Medical Center, Denver, Colorado, United States
TIPPS: Thrombophilia in Pregnancy Prophylaxis Study
- Conditions
- Interventions
- First Posted Date
- 2009-08-27
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 292
- Registration Number
- NCT00967382
- Locations
- 🇨🇦
SMBD Jewish General Hospital, Montreal, Quebec, Canada
🇨🇦Royal University Hospital, Saskatoon, Saskatchewan, Canada
🇨🇦QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients
- First Posted Date
- 2009-08-26
- Last Posted Date
- 2016-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 87
- Registration Number
- NCT00966277
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 38
- Registration Number
- NCT00952380
- Locations
- 🇸🇮
Lekarna, Univerzitetni klinicni center Ljubljana, Ljubljana, Slovenia
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸Investigational Drug Service Tampa General Hospital, Tampa, Florida, United States
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
- First Posted Date
- 2009-07-21
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 338
- Registration Number
- NCT00942968
- Locations
- 🇨🇦
University Health Network-Toronto General Hospital, Toronto, Ontario, Canada
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Bay Area Cancer Research Group, Pleasant Hill, California, United States
Effectiveness And Safety Of Dalteparin In Patients With Acute Coronary Syndromes Without ST Elevations In Clinical Practice
- First Posted Date
- 2009-06-17
- Last Posted Date
- 2012-01-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 618
- Registration Number
- NCT00922766
- Locations
- 🇮🇳
Pfizer Investigational Site, Kolkata, West Bengal, India
Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)
- Conditions
- Interventions
- First Posted Date
- 2008-11-06
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- Duke University
- Target Recruit Count
- 1884
- Registration Number
- NCT00786474
- Locations
- 🇺🇸
Duke Clinical Research Institute, Durham, North Carolina, United States
The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients (A6301086)
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2012-01-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 62
- Registration Number
- NCT00765063
- Locations
- 🇬🇧
Pfizer Investigational Site, Birmingham, United Kingdom
Alterations of Blood Clotting With the Use of Sequential Compression Devices on the Lower Limbs
- Conditions
- Interventions
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2013-11-05
- Lead Sponsor
- University of Parma
- Target Recruit Count
- 40
- Registration Number
- NCT00726570
- Locations
- 🇮🇹
University Hospital / Azienda Ospedaliero-Universitaria, Parma, PR, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.